FDA Grants Breakthrough Therapy Designation for Genentech’s Investigational Cancer Immunotherapy MPDL3280A (Anti-PDL1) in Non-Small Cell Lung Cancer

… MPDL3280A (Anti-PDL1) in Non-Small Cell Lung Cancer -- Second FDA Breakthrough Therapy … Death-Ligand 1) positive non-small cell lung cancer (NSCLC) whose disease has progressed … advanced stages. About Genentech in Lung Cancer Lung cancer is a major area of …